Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Chronic Heart Failure

Free Subscription Articles published in Cardiovasc Res Retrieve available abstracts of 105 articles: HTML format

Single Articles

August 2026
1. MENDIETA G, Pironti G, Tromp J, Lund LH, et al
   Inflammatory cytokines and immune signalling in heart failure: mechanisms, models and emerging therapies.
   Cardiovasc Res. 2026 Aug 13:cvag172. doi: 10.1093.
   PubMed     Abstract available
   
   
   
2. WOJNAR-LASON K, Stojak M, Kwiatkowski G, Giergiel M, et al
   Liver sinusoidal endothelial cell (LSEC) defenestration in chronic heart failure is primarily dependent on cardiac diastolic dysfunction and is reversed by sodium-glucose cotransporter 2 inhibitor but not by angiotensin-converting enzyme inhibitor.
   Cardiovasc Res. 2026 Aug 11:cvag168. doi: 10.1093.
   PubMed     Abstract available
   
   
   July 2026
3. NIKOLAEV VO, Gorelik J
   Cardiomyocyte T-tubule loss in heart failure - NFkappaB as a central signalling hub.
   Cardiovasc Res. 2026 Jul 14:cvag148. doi: 10.1093.
   PubMed    
   
   
   
4. ASKARINEJAD A, Luscher TF, Lip GYH
   Atrial fibrillation in patients with left ventricular non-compaction: incidence and associations with stroke, heart failure, and mortality.
   Cardiovasc Res. 2026 Jul 9:cvag156. doi: 10.1093.
   PubMed     Abstract available
   
   
   June 2026
5. LI Y, Sun Z, Duan H, Wu M, et al
   Syntabulin promotes heart failure by enhancing SR-mitochondria tethering and impairing mitofission.
   Cardiovasc Res. 2026 Jun 29:cvag139. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. MAZZOLA M, Wang H, Lang D, Balycheva M, et al
   Loss of caveolar A1 adenosine receptor signalling blunts anti-adrenergic control in heart failure.
   Cardiovasc Res. 2026 Jun 24:cvag131. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. WU LH, Pakkiri LS, Tromp J, Lim PL, et al
   Differential metabolomic prediction of outcomes in HFpEF and HFrEF: a prospective international multi-ethnic cohort study.
   Cardiovasc Res. 2026;122:1070-1086.
   PubMed     Abstract available
   
   
   
8. WANG Y, Jia D, Shi Y
   Targeting the ALCAT1 enzyme for the treatment of pressure-overload hypertrophy.
   Cardiovasc Res. 2026;122:1087-1103.
   PubMed     Abstract available
   
   
   
9. DEIMAN FE, Arslan T, de Brouwer R, Henry I, et al
   Plasma proteomics stratification identifies phospholamban R14del carriers at risk for disease progression.
   Cardiovasc Res. 2026;122:1104-1118.
   PubMed     Abstract available
   
   
   
10. CAPONE F, Rommel KP, Forbes M, Fahjen P, et al
    Integrated left ventricular multi-omics landscape of human cardiometabolic HFpEF.
    Cardiovasc Res. 2026;122:984-1000.
    PubMed     Abstract available
    
    
    May 2026
11. ELBASSIONI AAM, Raheem AA, Song J, Johnston AS, et al
    Targeting RUNX1 protects against diastolic dysfunction in a two-hit mouse model of heart failure with preserved ejection fraction.
    Cardiovasc Res. 2026 May 26:cvag106. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2026
12. GERGELY TG, Drobni ZD, Kovacs T, Sayour NV, et al
    Inhibition of the PD-1 immune checkpoint and the development of heart failure in the presence of prior cardiac ischemia.
    Cardiovasc Res. 2026 Apr 22:cvag085. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. ZHAO Y, Bao X, Xiong W, Wan X, et al
    Telomere recapping prevents pathogenic telomere-to-mitochondrial DNA communication in heart failure.
    Cardiovasc Res. 2026 Apr 6:cvag077. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2026
14. MARINO A, Cumps J, Guilbert L, Geiser A, et al
    Sodium-myo-inositol cotransporter-1, SMIT1, promotes cardiac hypertrophy and fibrosis induced by pressure overload in mice.
    Cardiovasc Res. 2026;122:578-592.
    PubMed     Abstract available
    
    
    
15. FURTADO M, Barbosa P, Wemans A, Zhang L, et al
    Shared splicing dysregulation in heart failure associated with dilated and ischemic cardiomyopathy and spatial specificity across cardiac regions.
    Cardiovasc Res. 2026 Mar 24:cvag068. doi: 10.1093.
    PubMed     Abstract available
    
    
    
16. ZHU C, Xue Y, Hong W, Zhu Y, et al
    Suppressor of variegation 3-9 homolog 1 deficiency attenuates cardiac fibrosis and rescues heart failure through TACC2.
    Cardiovasc Res. 2026 Mar 20:cvag066. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2026
17. PAN Q, Chen C, Zhang C, Jiang Y, et al
    Small extracellular vesicle-mediated adipocyte-cardiomyocyte crosstalk exacerbates heart failure with preserved ejection fraction.
    Cardiovasc Res. 2026 Feb 5:cvag030. doi: 10.1093.
    PubMed     Abstract available
    
    
    
18. KLEINBONGARD P, Beyer AM
    Telomer length, integrity vs. telomerase-activity - who is to blame for heart failure?
    Cardiovasc Res. 2026 Feb 3:cvag026. doi: 10.1093.
    PubMed    
    
    
    
19. HEGNER P, Baier MJ, Krammer T, Seitz S, et al
    Semaglutide improves contractile function in human atrial myocardium of patients with heart failure and preserved ejection fraction.
    Cardiovasc Res. 2026 Feb 3:cvag039. doi: 10.1093.
    PubMed    
    
    
    January 2026
20. KARAMPINOS KI, Farmakis D, Gurung R, Foo RS, et al
    Ferroptosis in heart failure: from molecular insights to therapeutic implications.
    Cardiovasc Res. 2026 Jan 31:cvag019. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. NAH J, Sung EA, Zhai P, Maejima Y, et al
    Cardiomyocyte-specific deficiency of C/EBPbeta aggravates pressure overload-induced heart failure.
    Cardiovasc Res. 2026 Jan 30:cvag029. doi: 10.1093.
    PubMed     Abstract available
    
    
    
22. BRANDT M, Khraisat S, Luo Q, Mayerle M, et al
    Integrative transcriptomic profiling links telomere dysfunction to cGAS-STING activation in heart failure signatures in mice and humans.
    Cardiovasc Res. 2026 Jan 22:cvag013. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2025
23. SILVA ED, Tome I, Vasques-Novoa F, Conceicao G, et al
    Pharmacological clearance of senescent cells reduces inflammation, endothelial damage and cardiac fibrosis in HFpEF.
    Cardiovasc Res. 2025;121:2385-2403.
    PubMed     Abstract available
    
    
    
24. RAMOVS V, Chen HS, Patra A, Tjokrodirijo R, et al
    KLHL24 mutation drives intermediate filament degradation, mitochondrial dysfunction and fibrosis in heart failure patients.
    Cardiovasc Res. 2025 Dec 5:cvaf231. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2025
25. HE M, Tay WT, Song N, Liu T, et al
    Cardioprotective role of RBFox1 in myocardial infarction-induced heart failure.
    Cardiovasc Res. 2025 Nov 26:cvaf206. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. ADRAH Y, Hegemann N, Faidel D, Kucherenko MM, et al
    Defining HFpEF in rodents: a systematic review.
    Cardiovasc Res. 2025;121:2134-2143.
    PubMed     Abstract available
    
    
    
27. MATSUMOTO S, Butt JH, Docherty KF, Jhund PS, et al
    Obesity, aldosterone, and natriuretic peptide in patients with heart failure and reduced ejection fraction.
    Cardiovasc Res. 2025 Nov 18:cvaf235. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. ZEDER K, Brown CH, Santi A, Cvirn L, et al
    The prevalence of pulmonary hypertension associated with left heart disease - a systematic review and meta-analysis.
    Cardiovasc Res. 2025 Nov 11:cvaf226. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. REDGRAVE RE, Booth LK, Richardson GD
    From immunosenescence to diastolic dysfunction: Tracing the senescence cascade in heart failure with preserved ejection fraction.
    Cardiovasc Res. 2025 Nov 8:cvaf220. doi: 10.1093.
    PubMed    
    
    
    October 2025
30. METHAWASIN M, Meinke S, Radke MH, Farman GP, et al
    Rbm20 antisense oligonucleotides alleviate diastolic dysfunction in a mouse model of cardiometabolic heart failure (HFpEF).
    Cardiovasc Res. 2025 Oct 17:cvaf171. doi: 10.1093.
    PubMed     Abstract available
    
    
    
31. DAGAN M, Beale A, Wang B, Vizi D, et al
    Insights into pulmonary remodelling in heart failure with preserved ejection fraction through transpulmonary biomarker gradients.
    Cardiovasc Res. 2025 Oct 16:cvaf196. doi: 10.1093.
    PubMed    
    
    
    
32. OBEIDAT M, Eisner DA
    A RADical approach to treating heart failure.
    Cardiovasc Res. 2025 Oct 10:cvaf184. doi: 10.1093.
    PubMed    
    
    
    
33. ELMORE G, Lohano SS, McVay NM, Levitan BM, et al
    RRAD-reduction reveals efficacy of targeting L-type calcium channel regulation for treatment of heart failure.
    Cardiovasc Res. 2025 Oct 1:cvaf169. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2025
34. CHUNG B, Jonas W, Rostami F, Malik Z, et al
    Iron regulatory proteins secure iron availability in skeletal muscle to preserve exercise tolerance in heart failure.
    Cardiovasc Res. 2025 Sep 25:cvaf173. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2025
35. HASTINGS MH, Zhou Q, Wu C, Shabani P, et al
    Cardiac ageing: from hallmarks to therapeutic opportunities.
    Cardiovasc Res. 2025;121:1474-1488.
    PubMed     Abstract available
    
    
    July 2025
36. BOGDANOV V, Mariangelo JIE, Soltisz AM, Sakuta G, et al
    Distinct intracellular spatiotemporal expression of Calmodulin genes underlies functional diversity of Calmodulin-dependent signalling in cardiac myocytes.
    Cardiovasc Res. 2025;121:1052-1065.
    PubMed     Abstract available
    
    
    June 2025
37. LI F, Du WW, Li X, Wen S, et al
    A new protein isoform encoded by human circular RNA circSLC8a1 contributes to cardiac remodelling.
    Cardiovasc Res. 2025;121:882-899.
    PubMed     Abstract available
    
    
    
38. RAYNER JJ, Abdesselam I, Pan J, Lewis AJM, et al
    Obesity and heart failure: exploring the cardiometabolic axis.
    Cardiovasc Res. 2025 Jun 3:cvaf090. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2025
39. CELIK S, Hyrefelt L, Czuba T, Li Y, et al
    Antisense-mediated regulation of exon usage in the elastic spring region of Titin modulates sarcomere function.
    Cardiovasc Res. 2025;121:629-642.
    PubMed     Abstract available
    
    
    April 2025
40. MIRA HERNANDEZ J, Shen EY, Ko CY, Hourani Z, et al
    Differential sex-dependent susceptibility to diastolic dysfunction and arrhythmia in cardiomyocytes from obese diabetic heart failure with preserved ejection fraction model.
    Cardiovasc Res. 2025;121:254-266.
    PubMed     Abstract available
    
    
    
41. WONG LL, Koh HWL, Choi H, Zou R, et al
    Combined circulating microRNA and peptide biomarkers for prognostication in heart failure.
    Cardiovasc Res. 2025 Apr 17:cvaf065. doi: 10.1093.
    PubMed    
    
    
    
42. JANSSEN-TELDERS C, Eringa EC, de Groot JR, de Man FS, et al
    The role of epicardial adipose tissue remodelling in heart failure with preserved ejection fraction.
    Cardiovasc Res. 2025 Apr 16:cvaf056. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2025
43. DAVIDSON SM, Andreadou I, Antoniades C, Bartunek J, et al
    Opportunities and challenges for the use of human samples in translational cardiovascular research: a scientific statement of the ESC Working Group on Cellular Biology of the Heart, the ESC Working Group on Cardiovascular Surgery, the ESC Council on B
    Cardiovasc Res. 2025 Mar 14:cvaf023. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2025
44. TIMMER LT, den Hertog E, Versteeg D, Post H, et al
    Cardiomyocyte SORBS2 expression increases in heart failure and regulates integrin interactions and extracellular matrix composition.
    Cardiovasc Res. 2025 Feb 17:cvaf021. doi: 10.1093.
    PubMed     Abstract available
    
    
    
45. SHANG R, Rodrigues B
    Cardioprotective effects of a 'twincretin' drug tirzepatide in heart failure following myocardial infarction.
    Cardiovasc Res. 2025 Feb 4:cvaf006. doi: 10.1093.
    PubMed    
    
    
    January 2025
46. STEFANSKA K, Sattar N
    Incretin-based weight loss therapies and heart failure with preserved ejection fraction: guideline impactful results, but mechanisms unclear.
    Cardiovasc Res. 2025 Jan 31:cvaf001. doi: 10.1093.
    PubMed    
    
    
    
47. SONI S, Skow RJ, Foulkes S, Haykowsky MJ, et al
    Therapeutic potential of ketone bodies on exercise intolerance in heart failure: looking beyond the heart.
    Cardiovasc Res. 2025 Jan 18:cvaf004. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2024
48. SCHWARZ KG, Pereyra KV, Diaz-Jara E, Vicencio SC, et al
    Brainstem C1 neurons mediate heart failure decompensation and mortality during acute salt loading.
    Cardiovasc Res. 2024 Dec 30:cvae261. doi: 10.1093.
    PubMed     Abstract available
    
    
    
49. FUKUMA N, Tokiwa H, Numata G, Ueda K, et al
    Endothelial oestrogen-myocardial cyclic guanosine monophosphate axis critically determines angiogenesis and cardiac performance during pressure overload.
    Cardiovasc Res. 2024;120:1884-1897.
    PubMed     Abstract available
    
    
    November 2024
50. TUBBEN A, Markousis-Mavrogenis G, Meems LMG, van Essen BJ, et al
    Circulating ECM proteins decorin and alpha-L-iduronidase differentiate ATTRwt-CM from ATTRwt-negative HFpEF/HFmrEF.
    Cardiovasc Res. 2024;120:1727-1736.
    PubMed     Abstract available
    
    
    
51. COROVIC A, Zhao X, Huang Y, Newland SR, et al
    Coronavirus disease 2019-related myocardial injury is associated with immune dysregulation in symptomatic patients with cardiac magnetic resonance imaging abnormalities.
    Cardiovasc Res. 2024;120:1752-1767.
    PubMed     Abstract available
    
    
    
52. ALHASAN KA, King MA, Pattar BSB, Lewis IA, et al
    Anaplerotic filling in heart failure: a review of mechanism and potential therapeutics.
    Cardiovasc Res. 2024 Nov 21:cvae248. doi: 10.1093.
    PubMed     Abstract available
    
    
    
53. MINISTRINI S, Camici GG
    Inflammation and heart failure: are we facing a "hedgehog's dilemma"?
    Cardiovasc Res. 2024 Nov 16:cvae246. doi: 10.1093.
    PubMed    
    
    
    
54. MONTUORO S, Gentile F, Giannoni A
    Neuroimmune cross-talk in heart failure.
    Cardiovasc Res. 2024 Nov 5:cvae236. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2024
55. SUN Q, Karwi QG, Wong N, Lopaschuk GD, et al
    Advances in myocardial energy metabolism: metabolic remodeling in heart failure and beyond.
    Cardiovasc Res. 2024 Oct 25:cvae231. doi: 10.1093.
    PubMed     Abstract available
    
    
    
56. FORTE M, Galli M, Sciarretta S
    Erbb3 and Hspa2, two novel predictors of heart failure in diabetic patients.
    Cardiovasc Res. 2024 Oct 25:cvae220. doi: 10.1093.
    PubMed    
    
    
    
57. NG YH, Koay YC, Marques FZ, Kaye DM, et al
    Leveraging metabolism for better outcomes in heart failure.
    Cardiovasc Res. 2024 Oct 1:cvae216. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2024
58. HU W, Tu H, Wadman MC, Li YL, et al
    Renal denervation achieves its antiarrhythmic effect through attenuating macrophage activation and neuroinflammation in stellate ganglia in chronic heart failure.
    Cardiovasc Res. 2024 Sep 25:cvae196. doi: 10.1093.
    PubMed     Abstract available
    
    
    
59. TAKAOKA M, Tadross JA, Al-Hadithi ABAK, Zhao X, et al
    GDF15 antagonism limits severe heart failure and prevents cardiac cachexia.
    Cardiovasc Res. 2024 Sep 23:cvae214. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. YANG R, Ruan B, Wang R, Zhang X, et al
    Cardiomyocyte betaII spectrin plays a critical role in maintaining cardiac function by regulating mitochondrial respiratory function.
    Cardiovasc Res. 2024;120:1312-1326.
    PubMed     Abstract available
    
    
    August 2024
61. CONNING-ROWLAND MS, Giannoudi M, Drozd M, Brown OI, et al
    The diabetic myocardial transcriptome reveals Erbb3 and Hspa2 as a novel biomarkers of incident heart failure.
    Cardiovasc Res. 2024 Aug 24:cvae181. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2024
62. TRUM M, Riechel J, Schollmeier E, Lebek S, et al
    Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF.
    Cardiovasc Res. 2024;120:999-1010.
    PubMed     Abstract available
    
    
    June 2024
63. GRECO CM, Nisoli E
    The ketogenic diet is unable to improve cardiac function in ischemic heart failure: an unexpected result?
    Cardiovasc Res. 2024 Jun 6:cvae126. doi: 10.1093.
    PubMed    
    
    
    May 2024
64. FORTE M, Frati G, Sciarretta S
    Phosphodiesterase-mediated modulation of subcellular cAMP levels to reduce heart failure.
    Cardiovasc Res. 2024 May 24:cvae108. doi: 10.1093.
    PubMed    
    
    
    
65. PAVLAKI N, Froese A, Li W, De Jong KA, et al
    Gene therapy with phosphodiesterases 2A and 4B ameliorates heart failure and arrhythmias by improving subcellular cAMP compartmentation.
    Cardiovasc Res. 2024 May 22:cvae094. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. HO KL, Karwi Q, Wang F, Wagg C, et al
    The ketogenic diet does not improve cardiac function and blunts glucose oxidation in ischemic heart failure.
    Cardiovasc Res. 2024 May 1:cvae092. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2024
67. KAHNERT K, Soattin L, Mills RW, Wilson C, et al
    Proteomics couples electrical remodelling to inflammation in a murine model of heart failure with sinus node dysfunction.
    Cardiovasc Res. 2024 Apr 25:cvae054. doi: 10.1093.
    PubMed     Abstract available
    
    
    
68. KASS DA
    Benchmarking pre-clinical heart failure with preserved ejection fraction models: can we do better?
    Cardiovasc Res. 2024 Apr 4:cvae059. doi: 10.1093.
    PubMed    
    
    
    March 2024
69. RANGREZ AY, Frey N
    Reverse cardio-oncology: is heart failure-mediated gut dysbiosis the mechanistic driver of colorectal cancer progression?
    Cardiovasc Res. 2024 Mar 28:cvae051. doi: 10.1093.
    PubMed    
    
    
    
70. KESIDOU D, Beqqali A, Baker AH
    The dual effects of miR-222 in cardiac hypertrophy: bridging pathological and physiological paradigms.
    Cardiovasc Res. 2024;120:217-219.
    PubMed    
    
    
    February 2024
71. KIZER JR
    The elusive quest for causality in adiponectin's bimodal relationship with cardiovascular disease: Mendelian randomization meets Janus.
    Cardiovasc Res. 2024;120:3-5.
    PubMed    
    
    
    
72. ROLSKI F, Tkacz K, Weglarczyk K, Kwiatkowski G, et al
    TNF-alpha protects from exacerbated myocarditis and cardiac death by suppressing expansion of activated heart-reactive CD4+ T cells.
    Cardiovasc Res. 2024;120:82-94.
    PubMed     Abstract available
    
    
    
73. DE WIT S, Geerlings L, Shi C, Dronkers J, et al
    Heart failure-induced microbial dysbiosis contributes to colonic tumour formation in mice.
    Cardiovasc Res. 2024 Feb 24:cvae038. doi: 10.1093.
    PubMed     Abstract available
    
    
    
74. GOTTHARDT M, Lehnart SE
    SERCA2a microdomain cAMP changes in heart failure with preserved ejection fraction.
    Cardiovasc Res. 2024 Feb 9:cvae030. doi: 10.1093.
    PubMed    
    
    
    January 2024
75. SUN Q, Guven B, Wagg CS, de Oliveira AA, et al
    Mitochondrial fatty acid oxidation is the major source of cardiac ATP production in heart failure with preserved ejection fraction.
    Cardiovasc Res. 2024 Jan 9:cvae006. doi: 10.1093.
    PubMed     Abstract available
    
    
    
76. ABOULEISA RRE, Tang XL, Ou Q, Salama AM, et al
    Gene therapy encoding cell cycle factors to treat chronic ischemic heart failure in rats.
    Cardiovasc Res. 2024 Jan 4:cvae002. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2023
77. LAI P, Hille SS, Subramanian H, Weigman R, et al
    Remodelling of cAMP dynamics within the SERCA2a microdomain in heart failure with preserved ejection fraction caused by obesity and type 2 diabetes.
    Cardiovasc Res. 2023 Dec 14:cvad178. doi: 10.1093.
    PubMed     Abstract available
    
    
    
78. LIU X, Li H, Hastings MH, Xiao C, et al
    miR-222 inhibits pathological cardiac hypertrophyand heart failure.
    Cardiovasc Res. 2023 Dec 12:cvad184. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2023
79. KATTIH B, Boeckling F, Shumliakivska M, Tombor L, et al
    Single-nuclear transcriptome profiling identifies persistent fibroblast activation in hypertrophic and failing human hearts of patients with longstanding disease.
    Cardiovasc Res. 2023;119:2550-2562.
    PubMed     Abstract available
    
    
    
80. CICCARELLI M, Pires IF, Bauersachs J, Bertrand L, et al
    Acute heart failure: mechanisms and pre-clinical models-a Scientific Statement of the ESC Working Group on Myocardial Function.
    Cardiovasc Res. 2023;119:2390-2404.
    PubMed     Abstract available
    
    
    
81. CORRADI F, Masini G, Bucciarelli T, De Caterina R, et al
    Iron deficiency in myocardial ischaemia: molecular mechanisms and therapeutic perspectives.
    Cardiovasc Res. 2023;119:2405-2420.
    PubMed     Abstract available
    
    
    
82. WU J, Subbaiah KCV, Hedaya O, Chen S, et al
    FAM210A regulates mitochondrial translation and maintains cardiac mitochondrial homeostasis.
    Cardiovasc Res. 2023;119:2441-2457.
    PubMed     Abstract available
    
    
    
83. BECHMANN LE, Emanuelsson F, Nordestgaard BG, Benn M, et al
    Genetic variation in solute carrier family 5 member 2 mimicking sodium-glucose co-transporter 2-inhibition and risk of cardiovascular disease and all-cause mortality: reduced risk not explained by lower plasma glucose.
    Cardiovasc Res. 2023;119:2482-2493.
    PubMed     Abstract available
    
    
    
84. ASHOUR D, Rebs S, Arampatzi P, Saliba AE, et al
    An interferon gamma response signature links myocardial aging and immunosenescence.
    Cardiovasc Res. 2023;119:2458-2468.
    PubMed     Abstract available
    
    
    October 2023
85. NIELSEN MB, Colak Y, Benn M, Mason A, et al
    Plasma adiponectin levels and risk of heart failure, atrial fibrillation, aortic valve stenosis, and myocardial infarction: large scale observational and Mendelian randomization evidence.
    Cardiovasc Res. 2023 Oct 28:cvad162. doi: 10.1093.
    PubMed     Abstract available
    
    
    
86. CUTHBERT JJ, Cleland JGF
    Should we resurrect acetazolamide as a diuretic for congestion due to heart failure?
    Cardiovasc Res. 2023 Oct 18:cvad148. doi: 10.1093.
    PubMed    
    
    
    September 2023
87. ZOCCALI C, Mallamaci F, Adamczak M, de Oliveira RB, et al
    Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association.
    Cardiovasc Res. 2023;119:2017-2032.
    PubMed     Abstract available
    
    
    August 2023
88. CHEN X, Li X, Wu X, Ding Y, et al
    Integrin beta-like 1 mediates fibroblast-cardiomyocyte crosstalk to promote cardiac fibrosis and hypertrophy.
    Cardiovasc Res. 2023;119:1928-1941.
    PubMed     Abstract available
    
    
    
89. VISTNES M, Erusappan PM, Sasi A, Norden ES, et al
    Inhibition of the extracellular enzyme A disintegrin and metalloprotease with thrombospondin motif 4 prevents cardiac fibrosis and dysfunction.
    Cardiovasc Res. 2023;119:1915-1927.
    PubMed     Abstract available
    
    
    July 2023
90. MARTIN TP, MacDonald EA, Bradley A, Watson H, et al
    RNA interference or small molecule inhibition of Runx1 in the border zone prevents cardiac contractile dysfunction following myocardial infarction.
    Cardiovasc Res. 2023 Jul 11:cvad107. doi: 10.1093.
    PubMed     Abstract available
    
    
    
91. DA DALT L, Cabodevilla AG, Goldberg IJ, Norata GD, et al
    Cardiac lipid metabolism, mitochondrial function and heart failure.
    Cardiovasc Res. 2023 Jul 1:cvad100. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2023
92. DAMMAN K, Testani J
    Cardiorenal interactions in heart failure - insights from recent therapeutic advances.
    Cardiovasc Res. 2023 Jun 26:cvad096. doi: 10.1093.
    PubMed     Abstract available
    
    
    
93. SMART CD, Fehrenbach DJ, Wassenaar JW, Agrawal V, et al
    Immune profiling of murine cardiac leukocytes identifies Trem2 as a novel mediator of hypertensive heart failure.
    Cardiovasc Res. 2023 Jun 14:cvad093. doi: 10.1093.
    PubMed     Abstract available
    
    
    
94. CHUNG B, Wang Y, Thiel M, Rostami F, et al
    Preemptive iron supplementation prevents myocardial iron deficiency and attenuates adverse remodelling after myocardial infarction.
    Cardiovasc Res. 2023 Jun 14:cvad092. doi: 10.1093.
    PubMed     Abstract available
    
    
    
95. BASSUK SS, Manson JE
    Marine omega-3 fatty acid supplementation and prevention of cardiovascular disease: update on the randomized trial evidence.
    Cardiovasc Res. 2023;119:1297-1309.
    PubMed     Abstract available
    
    
    
96. KANY S, Al-Taie C, Roselli C, Pirruccello JP, et al
    Association of genetic risk and outcomes in patients with atrial fibrillation: interactions with early rhythm control in the EAST-AFNET4 trial.
    Cardiovasc Res. 2023 Jun 2:cvad027. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2023
97. GROGAN A, Lucero EY, Jiang H, Rockman HA, et al
    Pathophysiology and pharmacology of G protein-coupled receptors in the heart.
    Cardiovasc Res. 2023;119:1117-1129.
    PubMed     Abstract available
    
    
    
98. 
    Corrigendum to: VEGF-B hypertrophy predisposes to transition from diastolic to systolic heart failure in hypertensive rats.
    Cardiovasc Res. 2023 May 15:cvad073. doi: 10.1093.
    PubMed    
    
    
    
99. DONG M, Chen D, Zhu Y, Yang S, et al
    Impaired regulation of MMP2/16-MLCK3 by miR-146a-5p increased susceptibility to myocardial ischaemic injury in aging mice.
    Cardiovasc Res. 2023;119:786-801.
    PubMed     Abstract available
    
    
    
100. PHANG RJ, Ritchie RH, Hausenloy DJ, Lees JG, et al
     Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy.
     Cardiovasc Res. 2023;119:668-690.
     PubMed     Abstract available
     
     
     March 2023
101. YANG X, Zhang M, Xie B, Peng Z, et al
     Myocardial brain-derived neurotrophic factor regulates cardiac bioenergetics through the transcription factor Yin Yang 1.
     Cardiovasc Res. 2023;119:571-586.
     PubMed     Abstract available
     
     
     
102. SAMUELSSON AM, Bartolomaeus TUP, Anandakumar H, Thowsen I, et al
     VEGF-B hypertrophy predisposes to transition from diastolic to systolic heart failure in hypertensive rats.
     Cardiovasc Res. 2023 Mar 23:cvad040. doi: 10.1093.
     PubMed     Abstract available
     
     
     
103. PARKSOOK WW, Williams GH
     Aldosterone and cardiovascular diseases.
     Cardiovasc Res. 2023;119:28-44.
     PubMed     Abstract available
     
     
     
104. FAYYAZ AU, Sabbah MS, Dasari S, Griffiths LG, et al
     Histologic and proteomic remodeling of the pulmonary veins and arteries in a porcine model of chronic pulmonary venous hypertension.
     Cardiovasc Res. 2023;119:268-282.
     PubMed     Abstract available
     
     
     
105. MARKOUSIS-MAVROGENIS G, Minich WB, Al-Mubarak AA, Anker SD, et al
     Clinical and prognostic associations of autoantibodies recognizing adrenergic/muscarinic receptors in patients with heart failure.
     Cardiovasc Res. 2023 Mar 8:cvad042. doi: 10.1093.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum